Women & HIV
Women & HIV
Gilead Submits Applications for FDA Approval of Elvitegravir and Cobicistat
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 29 June 2012 00:00
- Written by Liz Highleyman
On June 27 Gilead Sciences announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of its new integrase inhibitor, elvitegravir, for use in combination antiretroviral therapy for treatment-experienced adults with HIV. The following day the company also requested approval of its novel boosting agent cobicistat.
Quad Pill Matches Atripla and Atazanavir for First-line HIV Treatment
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 29 June 2012 00:00
- Written by Liz Highleyman
Gilead's investigational Quad pill, a 4-in-1 coformulation containing the second-generation integrase inhibitor elvitegravir and a new boosting agent, performed as well as either the 3-in-1 Atripla coformulation or the popular protease inhibitor atazanavir (Reyataz) in Phase 3 studies, researchers reported in the June 30, 2012, issue of The Lancet.
Dapivirine Vaginal Ring HIV Prevention Trial Launched in Africa
- Details
- Category: HIV Prevention
- Published on Wednesday, 20 June 2012 00:00
- Written by Press Release
The International Partnership for Microbicides (IPM) last week announced the start of large clinical trial testing whether a vaginal ring containing dapivirine can reduce women's risk of becoming infected with HIV.
CDC Review Finds No Link Between Hormonal Contraception and HIV Risk
- Details
- Category: HIV Sexual Transmission
- Published on Wednesday, 27 June 2012 00:00
- Written by Liz Highleyman
A data review by the U.S. Centers for Disease Control and Prevention (CDC) has failed to confirm a previously described association between injectable or oral hormonal contraceptives and increased likelihood of HIV infection or disease progression, researchers reported in the June 22, 2012, issue of Morbidity and Mortality Weekly Report.
ASCO 2012: Breast Cancer Outcomes among HIV Positive Women
- Details
- Category: Cancer/Malignancies
- Published on Tuesday, 05 June 2012 00:00
- Written by Liz Highleyman
Women with HIV can do well on a variety of different types of treatment for breast cancer, but they are prone to infections and blood cell deficiencies and may benefit from adjunct therapies, researchers reported at the American Society of Clinical Oncology Annual Meeting (ASCO 2012) taking place this week in Chicago.
Web Design and Development by